Literature DB >> 16705469

Brief reoxygenation episodes during chronic hypoxia enhance posthypoxic recovery of LV function: role of mitogen-activated protein kinase signaling pathways.

Sandrine Morel1, Giuseppina Milano, Kathi Mujynya Ludunge, Antonio F Corno, Michele Samaja, Sylvain Fleury, Christophe Bonny, Lukas Kappenberger, Ludwig K von Segesser, Giuseppe Vassalli.   

Abstract

Children with congenital cyanotic heart defects have worse outcomes after surgical repair of their heart defects compared with noncyanotic ones. Institution of extracorporeal circulation in these children exposes the cyanotic heart to reoxygenation injury. Mitogen-activated protein kinase (MAPK) signaling cascades are major regulators of cardiomyocyte function in acute hypoxia and reoxygenation. However, their roles in chronic hypoxia are incompletely understood. We determined myocardial activation of the three major MAPKs, c-Jun NH2-terminal kinase (JNK), extracellular signal-regulated kinase-1/2 (ERK1/2), and p38-MAPK in adult rats exposed to hypoxia (FIO2=0.10) for varying periods of time. Myocardial function was analyzed in isolated perfused hearts. Acute hypoxia stimulated JNK and p38-MAPK activation. Chronic hypoxia (2 weeks) was associated with increased p38-MAPK (but not JNK) activation, increased apoptosis, and impaired posthypoxic recovery of LV function. Brief normoxic episodes (1 h/day) during chronic hypoxia abolished p38-MAPK activation, stimulated MEK-ERK1/2 activation modestly, and restored posthypoxic LV function. In vivo p38-MAPK inhibition by SB203580 or SB202190 in chronically hypoxic rats restored posthypoxic LV function. These results indicate that sustained hypoxemia maintains p38-MAPK in a chronically activated state that predisposes to myocardial impairment upon reoxygenation. Brief normoxic episodes during chronic hypoxia prevent p38-MAPK activation and restore posthypoxic recovery of myocardial function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16705469     DOI: 10.1007/s00395-006-0596-1

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  7 in total

1.  Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia.

Authors:  Monica Fantacci; Paola Bianciardi; Anna Caretti; Thomas R Coleman; Anthony Cerami; Michael Brines; Michele Samaja
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-07       Impact factor: 11.205

2.  Chronic intermittent hypoxia affects the cytosolic phospholipase A2α/cyclooxygenase 2 pathway via β2-adrenoceptor-mediated ERK/p38 stimulation.

Authors:  Petra Micova; Klara Hahnova; Marketa Hlavackova; Barbara Elsnicova; Anna Chytilova; Kristyna Holzerova; Jitka Zurmanova; Jan Neckar; Frantisek Kolar; Olga Novakova; Jiri Novotny
Journal:  Mol Cell Biochem       Date:  2016-09-30       Impact factor: 3.396

Review 3.  The involvement of protein kinases in the cardioprotective effect of chronic hypoxia.

Authors:  N V Naryzhnaya; H-J Ma; L N Maslov
Journal:  Physiol Res       Date:  2020-11-02       Impact factor: 1.881

4.  Phosphodiesterase-5 inhibition mimics intermittent reoxygenation and improves cardioprotection in the hypoxic myocardium.

Authors:  Giuseppina Milano; Paola Bianciardi; Viviane Rochemont; Giuseppe Vassalli; Ludwig K von Segesser; Antonio F Corno; Marco Guazzi; Michele Samaja
Journal:  PLoS One       Date:  2011-11-28       Impact factor: 3.240

5.  Normoxic and hyperoxic cardiopulmonary bypass in congenital heart disease.

Authors:  Amir Mokhtari; Martin Lewis
Journal:  Biomed Res Int       Date:  2014-09-18       Impact factor: 3.411

6.  Upregulated ATF6 contributes to chronic intermittent hypoxia-afforded protection against myocardial ischemia/reperfusion injury.

Authors:  Weikun Jia; Zhao Jian; Jingwei Li; Lin Luo; Liang Zhao; Yang Zhou; Fuqin Tang; Yingbin Xiao
Journal:  Int J Mol Med       Date:  2016-03-22       Impact factor: 4.101

7.  Editorial - Hypoxia and Reoxygenation: From Basic Science to Bedside.

Authors:  Michele Samaja; Giuseppina Milano
Journal:  Front Pediatr       Date:  2015-10-19       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.